OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced the appointment of David P. Meininger, PhD, MBA, to the newly created position of Senior Vice President of Business Development, effective today. In this role, Dr. Meininger will be responsible for developing new business and strategic partnerships as well as potential licensing opportunities. He will also manage all corporate development activities for the Company’s therapeutic products.
“I’m thrilled to welcome David to the OncoSec team. David brings more than 20 years of experience in basic and applied scientific research, and has led growth-oriented teams at prominent biotech and pharmaceutical companies, including Merck. He also brings complimentary experience to OncoSec’s business development focus in the field of immuno-oncology,” said Punit Dhillon, CEO and President of OncoSec. “His extensive business experience and industry-acumen will provide immense value to OncoSec as we continue to expand our drug discovery and development activities.”
Most recently, Dr. Meininger served as Executive Director, Business Development and Licensing at Merck & Co., Inc., where he was the global lead for biologics technologies and was responsible for West Coast in-licensing opportunities in immuno-oncology and other therapy areas. Prior to his Business Development role at Merck, Dr. Meininger served as Executive Director, Molecular Discovery. In this position, he led a team focused on discovery, initial production, characterization, and validation of large-molecule leads for programs across seven Disease Area Franchises in addition to championing multiple biologics discovery initiatives, including several supporting KEYTRUDA® (pembrolizumab).
Prior to joining Merck, Dr. Meininger was Vice President, Biotherapeutics at Boehringer Ingelheim GmbH. While at Boehringer Ingelheim GmbH, he led the New Biological Entity Discovery Unit focusing on the discovery, design, and early development of New Biological Entities. He was also Principal Scientist, Department of Protein Science at Amgen Inc. where his team supported multiple Amgen Oncology and Inflammation Therapeutic Area projects.
Dr. Meininger earned a bachelor’s degree in chemistry from the University of Florida and a PhD in biochemistry from the University of California, San Diego. He also earned a MBA in technology management from the University of Washington. (Original Source)
Shares of OncoSec Medical Inc closed last Friday at $6.33. ONCS has a 1-year high of $6.45 and a 1-year low of $4.59. The stock’s 50-day moving average is $5.75 and its 200-day moving average is $6.30.
On the ratings front, OncoSec Medical has been the subject of a number of recent research reports. In a report issued on August 19, H.C. Wainwright analyst Mark Breidenbach initiated coverage with a Buy rating on ONCS and a price target of $25, which implies an upside of 294.9% from current levels. Separately, on August 18, Maxim Group’s Jason Kolbert reiterated a Buy rating on the stock and has a price target of $17.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Mark Breidenbach and Jason Kolbert have a total average return of -13.1% and -9.0% respectively. Breidenbach has a success rate of 37.5% and is ranked #3319 out of 3755 analysts, while Kolbert has a success rate of 34.9% and is ranked #3730.
OncoSec Medical Inc is a hybrid device and gene therapy biotechnology company. It is engaged in designing, developing and commercializing medical approaches for treatment of cancer.